Latest Orthocell News

Orthocell has appointed MontsMed as the exclusive distributor for its nerve repair product Remplir™ in Hong Kong, marking a significant step in its Asian commercialisation strategy. This move opens access to the vast Guangdong-Hong Kong-Macao Greater Bay Area, complementing existing operations in Singapore and planned expansion in Thailand.

Orthocell has boosted its investment in Marine Biomedical to secure exclusive global distribution rights for PearlBone™, an innovative bone substitute nearing FDA approval, enhancing its regenerative medicine portfolio.

Orthocell has raised $30 million through an institutional placement to accelerate the US commercialisation of its flagship nerve repair product Remplir and expand its regenerative medicine portfolio.

Orthocell Limited has reported a record $3 million quarterly revenue, driven by strong sales of its nerve repair product Remplir in Australia and Singapore, while advancing its rollout in the US and Canada ahead of schedule.

Orthocell has reported a record $3 million revenue for the September quarter, driven by strong sales of its nerve repair product Remplir™ in Australia and Singapore, with early US sales and Canadian market entry poised to accelerate growth.

Orthocell has appointed its first Canadian distributor for Remplir, its innovative nerve repair device, ahead of an official launch at a major surgical conference in Vancouver. The move marks a significant step in expanding the product’s international footprint.

Orthocell’s nerve repair device Remplir is being adopted in Australia for nerve-sparing prostate cancer surgeries, aiming to reduce erectile dysfunction and urinary incontinence post-operation. This development could significantly expand Remplir’s market reach globally.

Orthocell Limited reports an 81.1% overall treatment success rate from its Remplir Real World Evidence study, reinforcing the product’s safety and efficacy as it expands sales in the US and prepares regulatory submissions for the EU and UK.

Orthocell Ltd reported a record $9.23 million revenue for FY25, driven by strong sales of its nerve repair and dental products, alongside securing US FDA clearance for its flagship nerve repair device Remplir. The company is poised for accelerated growth as it expands its global commercial footprint.

Orthocell has achieved a significant milestone by recording its first US sales revenue for Remplir™, its flagship nerve repair product, shortly after FDA clearance and initial surgical use.

Orthocell Limited has reported a record FY2025 revenue of A$9.19 million, driven by strong sales of its nerve repair product Remplir™ in Australia and a promising US market launch following FDA clearance.

Orthocell Limited has posted a record quarterly revenue of A$2.73 million, driven by strong Australian sales of its nerve repair product Remplir™, with US market expansion poised to accelerate in FY26.